2025 Business Update

Summary by AI BETAClose X

Arecor Therapeutics plc reported a 2025 business update showing total revenue of £3.1 million, down from £5.1 million in 2024 due to the cessation of Tetris Pharma operations, but cash and cash equivalents increased to £6.1 million from £3.2 million, exceeding expectations. Key developments include a September 2025 co-development deal with Sequel Med Tech for AT278, an ultra-concentrated insulin, and a £7 million upfront payment from a £11 million royalty financing agreement with Ligand Pharmaceuticals. The company also advanced AT278 with a positive Type C meeting with the FDA regarding a Phase 2 clinical study design and filed a patent application for novel compositions to improve oral peptide bioavailability.

Disclaimer*

UK 100

Latest directors dealings